41459-71-6

Basic information

• Product Name: ethyl 6-methoxy-2-oxo-2H-chromene-3-carboxylate
• Synonyms: ethyl 6-methoxy-2-oxo-2H-chromene-3-carboxylate
• CAS NO: 41459-71-6
• Molecular Formula: C₁₃H₁₂O₅
• Molecular Weight: 248.23138
• Mol File: 41459-71-6.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 422.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.284±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ethyl 6-methoxy-2-oxo-2H-chromene-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 6-methoxy-2-oxo-2H-chromene-3-carboxylate(41459-71-6)
• EPA Substance Registry System: ethyl 6-methoxy-2-oxo-2H-chromene-3-carboxylate(41459-71-6)

Safety Data

• Hazardous Substances Data: 41459-71-6(Hazardous Substances Data)

Upstream product

• 672-13-9 2-hydroxy-5-methoxybenzaldehyde 
• 105-53-3 diethyl malonate 
• 18224-54-9 ethyl 3,3-bis(ethylsulfanyl)acrylate 
• 3702-98-5 ethyl 4,4,4-trichloroacetoacetate 
• 141-97-9 ethyl acetoacetate 
• 150-76-5 4-methoxy-phenol 

Downstream Products

• 41459-72-7 6-methoxy-2-oxo-2H-chromene-3-carbonitrile 
• 35924-44-8 6-methoxycoumarin-3-carboxylic acid 
• 245072-50-8 3-benzothiazol-2-yl-6-methoxycoumarin 

Relevant articles and documents

Synthesis of 3-arylated 3,4-dihydrocoumarins: Combining continuous flow hydrogenation with laccase-catalysed oxidation

A convenient arylation of diverse 3,4-dihydrocoumarins with a number of catechols is described leading to a new class of compounds. As key step, a laccase-catalysed oxidation/Michael addition sequence is applied using commercially available laccase from Agaricus bisporus. 3,4-Dihydrocoumarins were obtained in a rapid and facile two-step sequence starting from salicylaldehydes: The corresponding coumarins were synthesised through a Knoevenagel condensation in up to 83% yield followed by a quantitative reduction performed in a flow system. Combining the reductive flow reaction with the laccase-catalysed arylation also led to successful consecutive one-pot approaches. Overall, the enzyme-catalysed arylations were carried out with yields ranging from 63 to 94%.

Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity

A series of (3-hydroxypyridin-4-one)-coumarin hybrids were developed and investigated as potential multitargeting candidates for the treatment of Alzheimer's disease (AD) through the incorporation of iron-chelating and monoamine oxidase B (MAO-B) inhibition. This combination endowed the hybrids with good capacity to inhibit MAO-B as well as excellent iron-chelating effects. The pFe3+ values of the compounds were ranging from 16.91 to 20.16, comparable to more potent than the reference drug deferiprone (DFP). Among them, compound 18d exhibited the most promising activity against MAO-B, with an IC50 value of 87.9 nM. Moreover, compound 18d exerted favorable antioxidant activity, significantly reversed the amyloid-β1-42 (Aβ1-42) induced PC12 cell damage. More importantly, 18d remarkably ameliorated the cognitive dysfunction in a scopolamine-induced mice AD model. In brief, a series of hybrids with potential anti-AD effect were successfully obtained, indicating that the design of iron chelators with MAO-B inhibitory and antioxidant activities is an attractive strategy against AD progression.

Ros inhibitory activity and cytotoxicity evaluation of benzoyl, acetyl, alkyl ester, and sulfonate ester substituted coumarin derivatives

Background: A number of non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin, indomethacin, ibuprofen, flufenamic acid, and phenylbutazone are being clinically used to treat inflammatory disorders. These NSAIDs are associated with serious side